Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22068530 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MEN1ALDH1A1KMT2ATRPA1 | |
| SCHEMBL26170335 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MEN1ALDH1A1KMT2ATRPA1 | |
| SCHEMBL17449612 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MEN1ALDH1A1KMT2ATRPA1 | |
| SCHEMBL19788244 | 0.86 | KDM4E (0.30) | — | |
| SCHEMBL23749740 | 0.82 | TRPA1 (0.33) | L3MBTL1MEN1ALDH1A1KMT2ATRPA1 | |
| SCHEMBL17108529 | 0.79 | — | — | |
| SCHEMBL9980267 | 0.79 | — | — | |
| SCHEMBL17108528 | 0.79 | — | — | |
| SCHEMBL23551519 | 0.77 | L3MBTL1 (0.33) | L3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL23102986 | 0.77 | LMNA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-9932317-B2 | Quinazoline compounds and their use in therapy | IMPERIAL INNOVATIONS LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | IMPERIAL WHITE CITY INCUBATOR LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | GRUENENTHAL GMGH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-7329663-B2 | Substituted-triazolopyrimidines as anticancer agents | WYETH (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | FIBP, PFAS, FPR3 | L3MBTL1 4250/4885MEN1 624/4885ALDH1A1 4106/4885 |
| US-20150057263-A1 | Quinazoline Compounds And Their Use In Therapy | EZH2, EHMT1, HNMT | L3MBTL1 1575/4885MEN1 767/4885ALDH1A1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.